This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cubist To Present At August Investor Conference

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that company management will discuss Cubist’s business activities and financial outlook at investor conferences during August 2012.

  • On Wednesday, August 1, David McGirr, SVP and CFO; Greg Stea, SVP Commercial Operations; and Michael Tomsicek, SVP and Deputy CFO will host one-on-one meetings at the Goldman Sachs Small Caps One-on-One Summit at the Ritz-Carlton Hotel in Chicago. Eileen C. McIntyre, Senior Director, Investor Relations will be joining as well. These meetings will not be webcast.
  • On Thursday, August 9, Steven Gilman, EVP and CSO, will host one-on-one meetings at the UBS Biotech Summer 1x1 Conference in San Francisco. Mr. Gilman will be joined by Eileen C. McIntyre, Senior Director, Investor Relations. These meetings will not be webcast.
  • On Wednesday, August 15, Michael Bonney, CEO, will present at 10:55 a.m. ET at the Wedbush Securities 2012 Life Sciences Management Access Conference at the Le Parker Meridien in New York. The presentation will be accessible live through Cubist’s website at www.cubist.com in the Investor Relations Conference Calendar section and will remain available there for a period of 30 days after the presentation.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist’s website.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs